AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS – Trademark Portfolio
Entity Type: 03
AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 19 filings in this category. Currently, 17 trademarks are registered and 1 is pending. Notable registered marks include D-SORP, NOSWELL, RELLACT, VITA-IG, and CYSTOMIN. The owner is based in AMMAN.
AL FERDOUS COMPLEX/KING ABDULLAH II STREET
MEDICAL CITY
AMMAN , JO
Showing of trademarks Trademarks
Trademark Classifications
AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS have?
AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS has 19 U.S. trademarks filed with the USPTO. Of these, 17 registered, 1 pending, 1 cancelled.
What trademark classes does AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS file in?
AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS's most well-known trademarks?
AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS's registered trademark portfolio includes well-known marks such as D-SORP, NOSWELL, RELLACT, VITA-IG, and CYSTOMIN. These are among 17 currently registered trademarks in the portfolio.
What is AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS's trademark registration success rate?
AL SHAHD AL SAFI COMPANY FOR FOOD SUPPLEMENTS has a 94% trademark registration rate, with 17 out of 18 resolved applications resulting in successful registration. Currently, 1 application is pending review.